Clinical trials: Zoledronic Acid
Metastatic Cancer, Prostate Cancer
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
RATIONALE: Zoledronate may prevent or decrease skeletal (bone)-related events (such as pain or fractures) caused by bone metastases and androgen deprivation therapy.
- Trial name
- NCT00079001
- Testing
- zoledronic acid, androgen deprivation therapy, GnRH agonist
- Where
- 241 sites in United States, Canada
- Volunteers
- 645 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Heart Transplantation, Liver Transplantation
Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation
The purpose of this study is to compare the effectiveness and safety of zoledronic acid with alendronate in the prevention of bone loss after organ transplantation. Zoledronic acid is given as a single intravenous infusion.
- Conditions
- Heart Transplantation, Liver Transplantation, Bone Resorption
- Trial name
- CTX (NCT00297830)
- Testing
- Zoledronic acid, Alendronate
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Columbia University
Prostate Cancer
PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer
The primary goal for this trial is to assess the change in PET scans with the administration of zoledronate (bisphosphonate) therapy in patients with metastatic prostate cancer.
- Trial name
- NCT01205646
- Testing
- zoledronate therapy, PET Scan
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Breast Neoplasms
Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer
This study will evaluate the safety/efficacy of zoledronic acid when given by intravenous infusion every 4 weeks in addition to letrozole as endocrine therapy in postmenopausal patients with hormone responsive breast cancer
- Trial name
- FEMZONE (NCT00375752)
- Testing
- Letrozole, Zolendronic Acid
- Where
- 27 sites in Germany
- Volunteers
- 168 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Lymphoma
Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant
RATIONALE: Zoledronic acid, vitamin D, and calcium may prevent bone loss in patients who are undergoing donor stem cell transplant.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Osteoporosis
- Trial name
- NCT00321932
- Testing
- calcium, cholecalciferol, zoledronic acid
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- University of Minnesota
Mesothelioma
Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)
The primary objective of this trial is to determine the response rate of single agent zoledronic acid using a composite of criteria including the EORTC modified RECIST criteria and the EORTC tumor response criteria for 18F-FDG…
- Trial name
- UAB0901 (NCT01204203)
- Testing
- Zometa
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Alabama at Birmingham
Paget's Disease of Bone
Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period
The primary objective of this core study was to show non-inferiority of zoledronic acid to risedronate, with respect to the proportion of patients who achieved therapeutic response.
- Trial name
- NCT00103740
- Testing
- zoledronic acid, Risedronate, Calcium and vitamin D supplements
- Where
- 41 sites in United States, Australia and 8 more
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Breast Neoplasms, Osteoporosis
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
This protocol is designed to compare the effect on bone of Zoledronic Acid 4 mg every 6 months when given upfront versus delayed start (based on a post-baseline BMD T- Score below -2.0 SD at either the lumbar spine or total hip…
- Trial name
- NCT00050011
- Testing
- Zoledronic Acid, Letrozole
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 602 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer, Metastatic Cancer
Zoledronic Acid and Positron Emission Tomography in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: A positron emission tomography scan is a procedure in which a small amount of radioactive sugar is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where…
- Trial name
- NCT00559897
- Testing
- 3'-deoxy-3'-[18F]FLT, Single photon emission computed tomography
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Malignant Pleural Effusion, Non Small Cell Lung Cancer
Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer
The purpose of this study is to evaluate whether the addition of the bisphosphonate Zometa (zoledronic acid) used along with standard regimens of chemotherapy, will help to control the need for palliative intervention of…
- Trial name
- ZAP (NCT01004510)
- Testing
- zoledronic acid
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Peter Bushunow MD
Bariatric Surgery Candidate
Pilot Study for Zoledronic Acid to Prevent Bone Loss After Bariatric Surgery
This study evaluates whether zoledronic acid can prevent the high bone turnover that occurs after Roux-en-Y Gastric Bypass (RYGB) and sleeve gastrectomy (SG) surgery.
- Trial name
- NCT03424239
- Testing
- Zoledronic Acid, Calcium citrate + vitamin D, Vitamin D3
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Massachusetts General Hospital
Carcinoma, Non-Small Cell Lung, Carcinoma, Small Cell Lung
Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer
The purpose of this study is to evaluate a new blood test as a way to follow the effect of Zometa in treating bone metastases due to lung cancer.
- Conditions
- Carcinoma, Non-Small Cell Lung, Carcinoma, Small Cell Lung, Metastases
- Trial name
- NCT00265200
- Testing
- zoledronic acid
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Louisville
Renal Insufficiency
Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants
The study is designed to look at the effect of different bone treatment plans on bone loss after kidney or kidney/pancreas transplant.
- Trial name
- NCT00580047
- Testing
- Zoledronic Acid, Calcium with vitamin D, Alendronate
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- University of Nebraska
Osteoporosis
Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass
This study will evaluate the efficacy of acetaminophen or fluvastatin in reducing the rate of occurrence and the severity of post dose symptoms that may occur during the 3 day period following a zoledronic acid infusion in post…
- Trial name
- NCT00489424
- Testing
- Acetaminophen, Fluvastatin
- Where
- United States
- Volunteers
- 793 people
- Sponsor
- Novartis Pharmaceuticals
Fractures, Bone
A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors
This is a randomized, double-blind, double-dummy study designed to provide bridging data in an Asian population to Amgen's studies of denosumab in subjects with bone metastases from solid tumors.
- Trial name
- NCT01920568
- Testing
- Denosumab 70 mg/mL, Zoledronic acid 4 mg, Calcium supplement
- Where
- 25 sites in China, Singapore and 1 more
- Volunteers
- 487 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid
The purpose of this study is to examine the effect of simvastatin and zoledronic acid on M-protein and/or free light chains when added to conventional chemotherapy for the treatment of multiple myeloma patients.
- Trial name
- NCT01772719
- Testing
- Simvastatin and zoledronic acid
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Louisville
Avascular Necrosis of Femoral Head
Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head
The purpose of this study is to test the effect of zoledronic acid over 2 years in preventing early collapse and progression of joint dome depression (≥ 2 mm by X-ray) of the femoral head in patients with large (> 30%: criteria…
- Trial name
- EZAPCOFH (NCT00939900)
- Testing
- zoledronic acid (aclasta)
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Seoul National University Bundang Hospital
Solid Tumor, Osteosarcoma
Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma
This is a prospective open-labeled phase I trial based on a dose escalating study design assessing two dose levels of sirolimus when prescribed in combination with metronomic cyclophosphamide (CP), methotrexate (MT) and…
- Trial name
- METZOLIMOS (NCT02517918)
- Testing
- Sirolimus combined with CP, MT and ZA
- Where
- 3 sites in France
- Volunteers
- 23 people
- Sponsor
- Institut Bergonié
Breast Cancer, Bone Metastases
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
The goal of this clinical research study is to find the highest tolerable dose of dasatinib and Zometa (zoledronic acid) that can be given in combination for the treatment of breast cancer that has spread to the bone.
- Trial name
- NCT00566618
- Testing
- Dasatinib, Zoledronic Acid
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Post Menopausal Osteoporosis
Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis
This study will compare the effectiveness of denosumab treatment every 6 months with once yearly zoledronic acid treatment on bone mineral density (BMD) at various skeletal sites.
- Trial name
- NCT01732770
- Testing
- Denosumab, Zoledronic Acid
- Where
- 45 sites in United States, Australia and 5 more
- Volunteers
- 643 people
- Sponsor
- Amgen